PATHOPHYSIOLOGY OF ENDOTOXIN-MEDIATED FEVER
内毒素介导的发热的病理生理学
基本信息
- 批准号:2750925
- 负责人:
- 金额:$ 21.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-09-01 至 2000-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Applicant's abstract) Fever is the hallmark of infection. It
is generally believed that it is caused not by exogenous, but by endogenous
pyrogens, members of an array of peptide mediators called cytokines. These
are elaborated and released into the circulation largely by systemic
mononuclear phagocytes activated by the exogenous agents, and transported to
the preoptic anterior hypothalamic area (POA) of the brain, where they act.
Prostaglandin E2 (PGE2) is thought to be a fever mediator in the POA,
induced by these cytokines. Although the intrapreoptic level of PGE2 rises
rapidly following the intravenous (iv) administration of exogenous (e.g.,
lipopolysaccharides, LPS) or endogenous pyrogens, recent data indicate that
these substances cannot account directly for the rapid production of PGE2
because it is initiated well before the synthase that they stimulate
(cyclooxygenase-2, COX-2) becomes active. Moreover, cytokines also are not
detectable in blood following iv LPS until after the febrile response is
already underway, and there is no evidence that they can readily penetrate
the brain. Hence, other, more quickly evoked mediators may be presumed to
be involved in initiating the febrile response. Based on well-recognized
mechanisms of LPS action and on new data regarding the induction of PGE2
synthesis, we have hypothesized that 1) iv LPS virtually immediately
activates the complement cascade, generating the anaphylatoxins C3a, C4a,
and C5a, which 2) function to rapidly induce various mediators, e.g.,
platelet-activating factor (PAF), bradykinin (BK), that 3) have the capacity
to stimulate the formation of nitric oxide (NO) which, in turn, 4) induces
PGE2 and, consequently, fever. We have preliminary evidence supporting the
involvement of systemic complement and of nitric oxide in the organum
vasculosum laminae terminalis (OVLT, the interface between the brain and
circulating pyrogens) in the febrile response to iv LPS. The purpose of
this proposed research is to substantiate the putative roles of complement
and NO in the pyrogenic response to iv LPS, and to determine whether PAF
and/or BK are factors that may link the two. If confirmed, this hypothesis
would allow formulating a novel, specific concept of the pathophysiology of
LPS-mediated fever, particularly regarding the onset of this response. The
results will be relevant to the still essentially unknown central nervous
mechanisms underlying the multivariate host defense reactions to infectious
pathogens.
描述:(申请人摘要)发热是感染的标志。 它
一般认为,它不是由外源性的,而是由内源性的
热原,称为细胞因子的肽介质阵列的成员。 这些
主要是由系统性的
单核吞噬细胞被外源性试剂激活,并被转运到
大脑的视前下丘脑前部区域(POA),它们在那里起作用。
前列腺素E2(PGE 2)被认为是POA中的发热介质,
由这些细胞因子引起的。 虽然PGE 2水平升高,
在静脉内(iv)施用外源性(例如,
脂多糖,LPS)或内源性热原,最近的数据表明,
这些物质不能直接解释PGE 2的快速产生
因为它比它们刺激的合成酶早启动
(环氧合酶-2,考克斯-2)变得活跃。 此外,细胞因子也不是
在静脉注射LPS后血液中可检测到,直到发热反应后,
已经在进行中,没有证据表明他们可以轻易地渗透
大脑 因此,其他更快诱发的介质可能被假定为
参与引发发热反应。 基于公认的
LPS作用机制和关于PGE 2诱导的新数据
合成,我们假设1)静脉注射LPS几乎立即
激活补体级联,产生过敏毒素C3 a,C4 a,
和C5 a,其2)用于快速诱导各种介质,例如,
血小板活化因子(PAF)、缓激肽(BK),即3)具有
刺激一氧化氮(NO)的形成,这反过来又诱导
前列腺素E2,因此,发烧。 我们有初步证据支持
全身补体和一氧化氮在器官中的参与
终板血管膜(OVLT,脑与
循环热原)对iv LPS的发热反应。 的目的
这项研究的目的是为了证实补体的作用。
和NO在iv LPS致热原反应中的作用,并确定PAF是否
和/或BK是可能将两者联系起来的因素。 如果得到证实,
将允许制定一个新的,具体的概念的病理生理学,
LPS介导的发热,特别是关于这种反应的开始。 的
结果将与本质上仍然未知的中枢神经系统相关。
多种宿主对感染性疾病防御反应的机制
病原体
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CLARK M BLATTEIS其他文献
CLARK M BLATTEIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CLARK M BLATTEIS', 18)}}的其他基金
PGE2 AND FEVER: INSIGHTS FROM TRANSGENIC MICE MODELS
PGE2 和发烧:来自转基因小鼠模型的见解
- 批准号:
6609674 - 财政年份:2000
- 资助金额:
$ 21.42万 - 项目类别:
PGE2 AND FEVER: INSIGHTS FROM TRANSGENIC MICE MODELS
PGE2 和发烧:来自转基因小鼠模型的见解
- 批准号:
6394115 - 财政年份:2000
- 资助金额:
$ 21.42万 - 项目类别:
PGE2 AND FEVER: INSIGHTS FROM TRANSGENIC MICE MODELS
PGE2 和发烧:来自转基因小鼠模型的见解
- 批准号:
6197592 - 财政年份:2000
- 资助金额:
$ 21.42万 - 项目类别:
PGE2 AND FEVER: INSIGHTS FROM TRANSGENIC MICE MODELS
PGE2 和发烧:来自转基因小鼠模型的见解
- 批准号:
6540083 - 财政年份:2000
- 资助金额:
$ 21.42万 - 项目类别:
相似海外基金
Negative allosteric modulators for bradykinin B1 receptors
缓激肽 B1 受体的负变构调节剂
- 批准号:
10680762 - 财政年份:2023
- 资助金额:
$ 21.42万 - 项目类别:
Excitatory effect of bradykinin on intracardiac neurons
缓激肽对心内神经元的兴奋作用
- 批准号:
19K07287 - 财政年份:2019
- 资助金额:
$ 21.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of cleaving enzymes activities for bradykinin in hereditary angioedema
遗传性血管性水肿中缓激肽裂解酶活性分析
- 批准号:
19K17917 - 财政年份:2019
- 资助金额:
$ 21.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Augmentation of tumor-target delivery of nanomedicine by an acid-responsive N-(2-hydroxypropyl)methacrylamide-based polymer-bradykinin conjugate.
通过酸响应性 N-(2-羟丙基)甲基丙烯酰胺基聚合物-缓激肽缀合物增强纳米药物的肿瘤靶向递送。
- 批准号:
18K06773 - 财政年份:2018
- 资助金额:
$ 21.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of bradykinin receptor 2 in tPA stroke therapy
缓激肽受体 2 在 tPA 中风治疗中的作用
- 批准号:
9767297 - 财政年份:2018
- 资助金额:
$ 21.42万 - 项目类别:
Studies for the evaluation of bradykinin cleaving enzymes and the establishment of Japanese disease condition of hereditary angioedema
缓激肽裂解酶的评价及日本遗传性血管性水肿病况的建立研究
- 批准号:
26461493 - 财政年份:2014
- 资助金额:
$ 21.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Endothelial bradykinin receptors as therapeutic targets
内皮缓激肽受体作为治疗靶点
- 批准号:
290821 - 财政年份:2013
- 资助金额:
$ 21.42万 - 项目类别:
Operating Grants
Evaluating the potential of chemotherapy and bradykinin inhibitors combination therapy to increase drug distribution in solid tumors
评估化疗和缓激肽抑制剂联合治疗增加实体瘤药物分布的潜力
- 批准号:
297040 - 财政年份:2013
- 资助金额:
$ 21.42万 - 项目类别:
Miscellaneous Programs
Role of the Bradykinin Pathway in Craniofacial Development
缓激肽通路在颅面发育中的作用
- 批准号:
8725637 - 财政年份:2012
- 资助金额:
$ 21.42万 - 项目类别:
the bradykinin system in endometriosis
子宫内膜异位症中的缓激肽系统
- 批准号:
24791687 - 财政年份:2012
- 资助金额:
$ 21.42万 - 项目类别:
Grant-in-Aid for Young Scientists (B)